WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/062054    International Application No.:    PCT/US2008/082826
Publication Date: 14.05.2009 International Filing Date: 07.11.2008
A61K 39/395 (2006.01), A61P 35/00 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel (CH) (For All Designated States Except US).
XOMA TECHNOLOGY LTD [--/US]; c/o 2910 Seventh Street, Berkeley, CA 94710 (US) (For All Designated States Except US).
LUQMAN, Mohammad [US/US]; (US) (For US Only).
WANG, Yongyu [US/US]; (US) (For US Only).
KANTAK, Seema [US/US]; (US) (For US Only).
HSU, Ssucheng, J. [US/US]; (US) (For US Only).
MIRZA, Amer, M. [US/US]; (US) (For US Only)
Inventors: LUQMAN, Mohammad; (US).
WANG, Yongyu; (US).
KANTAK, Seema; (US).
HSU, Ssucheng, J.; (US).
MIRZA, Amer, M.; (US)
Agent: HENRY, Leslie, T.; Alston & Bird LLP Bank Of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 (US)
Priority Data:
61/002,545 09.11.2007 US
Abstract: front page image
(EN)This invention relates to new uses of anti-CD40 antibodies in the- treatment of diseases or conditions associated with neoplastic B-cell growth in particular use of anti-CD40 antibodies in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). The invention is particularly useful for the treatment of patients who have previously been administered (i) CHOP, (ii) the chimeric anti-CD20 monoclonal antibody rituximab, or (iii) combination therapy with CHOP and rituximab.
(FR)L'invention concerne de nouvelles utilisations d'anticorps anti-CD40 dans le traitement de maladies ou d'affections associées à la croissance des lymphocytes B néoplasiques, en particulier l'utilisation d'anticorps anti-CD40 combinés à de la cyclophosphamide, de la doxorubicine, de la vincristine et de la prednisone (CHOP). La présente invention est particulièrement utile dans le traitement de patients ayant reçu préalablement une administration : (i) de CHOP, (ii) de rituximab, anticorps monoclonal chimérique anti-CD20 ou (iii) d'un traitement combiné de CHOP et de rituximab.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)